Guardant Health initiated with neutral view at Wolfe Research, here’s why

As previously reported, Wolfe Research analyst Doug Schenkel initiated coverage of Guardant Health with a Peer Perform rating and no price target. While “enthused” about the outlook for liquid biopsy testing in cancer and respecting Guardant’s “leadership in therapy selection,” the analyst says Street expectations “ostensibly already assume that a lot does go right” despite uncertainties surrounding growth drivers and operating plans.